Citations

Showing 10 of 108083 citations.

Variants in CLDN5 cause a syndrome characterized by seizures, microcephaly and brain calcifications
Deshwar, Ashish R. , Cytrynbaum, Cheryl , Murthy, Harsha, Zon, Jessica, Volpatti, Jonathan, Newbury‐Ecob, Ruth , Yu, Emily, Walker, Suzi, Scherer, Stephen W. , Mahida, Sonal , Elitt, Christopher M. , Nicolas, Gaël , Goldenberg, Alice , Saugier-Véber, Pascale , Lecoquierre, François , Dabaj, Ivana , Meddaugh, Hannah, Marble, Michael , Keppler‐Noreuil, Kim M. , Drayson, Lucy, Barañano, Kristin , Chassevent, Anna , Agre, Katie, Létard, Pascaline , Laquerrière, Annie, Ramsey, Keri , Henderson, Lindsay B. , Brady, Lauren , Tarnopolsky, Mark A. , Bainbridge, Matthew N. , Friedman, Jennifer , Capri, Yline , Athayde, Larissa Sampaio de, Ramos, Luiza , Blaser, Susan , Scherer, Stephen W , Nicolas, Gaël , Dabaj, Ivana , Dowling, James J , Lecoquierre, Francois , Tarnopolsky, Mark , Chitayat, David A. , Ellard, Sian , Allen, Hana Lango , Noche, Ramil R. , Bilan, Frédéric , Guyader, Gwenaël Le , Kok, Fernando , Gurgel‐Giannetti, Juliana , Weksberg, Rosanna

Mayo Clinic

Brain | December 8, 2022 | Volume: 146 | Issue: 6 | Pages: 2285-2297

10.1093/brain/awac461 | PMID 36477332 Get It

Abstract The blood–brain barrier ensures CNS homeostasis and protection from injury. Claudin-5 (CLDN5), an important component of tight junctions, is critical for the integrity of the blood–brain barrier. We have identified de novo heterozygous missense variants in CLDN5 in 15 unrelated patients who presented with a shared constellation of features including developmental delay, seizures (primarily infantile onset focal epilepsy), microcephaly and a recognizable pattern of pontine atrophy and brain calcifications. All variants clustered in one subregion/domain of the CLDN5 gene and the recurrent variants demonstrate genotype–phenotype correlations. We modelled both patient variants and loss of function alleles in the zebrafish to show that the variants analogous to those in patients probably result in a novel aberrant function in CLDN5. In total, human patient and zebrafish data provide parallel evidence that pathogenic sequence variants in CLDN5 cause a novel neurodevelopmental disorder involving disruption of the blood–brain barrier and impaired neuronal function.
Advances in Virtual Surgical Planning and Three-Dimensional Printing in Facial Reconstruction and Aesthetic Surgery
Sharaf, Basel , Sharaf, Basel A , Mardini, Samir

Mayo Clinic

Seminars in Plastic Surgery | December 7, 2022 | Volume: 36 | Issue: 03 | Pages: 132-132

10.1055/s-0042-1757565 | PMID 36506275 Get It

Black Bone MRI for Virtual Surgical Planning in Craniomaxillofacial Surgery
Vyas, Krishna S. , Suchyta, Marissa , Suchyta, Marissa A, Hunt, Christopher H. , Gibreel, Waleed , Mardini, Samir

Mayo Clinic

Seminars in Plastic Surgery | December 7, 2022 | Volume: 36 | Issue: 03 | Pages: 192-198

10.1055/s-0042-1756451 | PMID 36506277 Get It

AbstractAdvances in computer-aided design and computer-aided manufacturing software have improved translational applications of virtual surgical planning (VSP) in craniomaxillofacial surgery, allowing for precise and accurate fabrication of cutting guides, stereolithographic models, and custom implants. High-resolution computed tomography (CT) imaging has traditionally been the gold standard imaging modality for VSP in craniomaxillofacial surgery but delivers ionizing radiation. Black bone magnetic resonance imaging (MRI) reduces the risks related to radiation exposure and has comparable functionality when compared with CT for VSP. Our group has studied the accuracy of utilizing black bone MRI in planning and executing several types of craniofacial surgeries, including cranial vault remodeling, maxillary advancement, and mandibular reconstruction using fibular bone. Here, we review clinical applications of black bone MRI pertaining to VSP and three-dimensional (3D)-printed guide creation for craniomaxillofacial surgery. Herein, we review the existing literature and our institutional experience comparing black bone MRI and CT in VSP-generated 3D model creation in cadaveric craniofacial surgeries including cranial vault reconstruction, maxillary advancement, and mandibular reconstruction with fibular free flap. Cadaver studies have demonstrated the ability to perform VSP and execute the procedure based on black bone MRI data and achieve outcomes similar to CT when performed for cranial vault reshaping, maxillary advancement, and mandibular reconstruction with free fibula. Limitations of the technology include increased time and costs of the MRI compared with CT and the possible need for general anesthesia or sedation in the pediatric population. VSP and 3D surgical guide creation can be performed using black bone MRI with comparable accuracy to high-resolution CT scans in a wide variety of craniofacial reconstructions. Successful segmentation, VSP, and 3D printing of accurate guides from black bone MRI demonstrate potential to change the preoperative planning standard of care. Black bone MRI also reduces exposure to ionizing radiation, which is of particular concern for the pediatric population or patients undergoing multiple scans.
Point of Care Virtual Surgical Planning and 3D Printing in Facial Feminization Surgery
Sharaf, Basel , Bite, Uldis, Sharaf, Basel A , Kuruoglu, Doga , Morris, Jonathan M.

Mayo Clinic

Seminars in Plastic Surgery | December 7, 2022 | Volume: 36 | Issue: 03 | Pages: 164-168

10.1055/s-0042-1754388 | PMID 36506273 Get It

AbstractThe use of virtual surgical planning (VSP) and three-dimensional printing (3DP) technologies in the routine facial feminization surgery practice has gained a significant popularity over the past few years. The clinical applications of them are claimed to improve safety, accuracy, and efficiency of facial feminization surgeries. In this article, we review and discuss the current applications of VSP and 3DP in different facial feminization procedures.
Effect of Maintaining Immunosuppression After Kidney Allograft Failure on Mortality and Retransplantation
Balakrishnan, Suryanarayanan, Kukla, Aleksandra, Merzkani, Massini , Stegall, Mark, Smith, Byron H. , Bentall, Andrew , Kukla, Aleksandra , Stegall, Mark D. , Schinstock, Carrie A.

Mayo Clinic

Transplantation Direct | December 7, 2022 | Volume: 9 | Issue: 1 | Pages: e1415

10.1097/txd.0000000000001415 | PMID 36518791 Get It

Background. Few studies have addressed immunosuppression management after allograft failure (AF). Immunosuppression withdrawal to minimize complications must be balanced with the risk of sensitization and potentially reduced retransplantation. We aimed to determine relationships between immunosuppression, death, sensitization, and retransplantation among patients with AF. Methods. We performed a single-center retrospective study of patients transplanted from October 2007 to May 2017 with AF. We collected data on demographics, immunosuppression, calculated panel reactive antibody (cPRA) levels, death, retransplantation, and dialysis. Cox regression models were used to evaluate factors associated with death and retransplantation. Results. From October 2007 to May 2017, 1354 solitary ABO-compatible transplants were performed, of which 97 failed. Ten percent of patients received a preemptive retransplant. Among those who returned to dialysis (n = 87), 35% died, 25% received another transplant, and 30% remained on dialysis. After AF, 46% of patients discontinued immunosuppression. The cPRA was unchanged if immunosuppression was maintained, but immunosuppression discontinuation was associated with increased cPRA from a median (interquartile range) of 18 (0–99) to 96 (88.5–100.0; P = 0.003). Age at failure (hazard ratio, 1.1; confidence interval, 1.0-1.1) and cardiovascular disease were associated with death (hazard ratio, 2.9; confidence interval, 1.2-7.0) in multivariate analysis. Importantly, immunosuppression maintenance was not associated with increased death or retransplantation despite the increase in cPRA that occurred when immunosuppression was discontinued. Conclusions. Kidney transplant recipients with AF have a high mortality rate after dialysis initiation. Although immunosuppression withdrawal was associated with increased cPRA, it was not associated with reduced retransplantation. Therefore, it is reasonable to discontinue immunosuppression after AF despite sensitization if retransplantation is delayed.
Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results
Macklin‐Mantia, Sarah K. , Hodge, David O. , Riegert‐Johnson, Douglas L. , Hines, Stephanie L., Clift, Kristin E, Riegert-Johnson, Douglas, Clift, Kristin , Maimone, Santo

Mayo Clinic

Journal of Genetic Counseling | December 7, 2022 | Volume: 32 | Issue: 3 | Pages: 598-606

10.1002/jgc4.1665 | PMID 36478495 Get It

AbstractAdvances have dated the genetic testing initially offered to evaluate for hereditary breast and ovarian cancer risks. Previous research has demonstrated that many patients have not updated testing. This study reviewed the incidence of additional analysis after an uninformative BRCA1/2 result and offered updated testing with limited barriers to those who had not completed. After viewing an educational video and providing informed consent, eligible patients were mailed a saliva collection kit to complete an 84‐gene hereditary cancer panel at no personal cost. A total of 704 patients had completed BRCA1/2 only testing between 2001 and 2020. Fifteen percent (N = 102) of the 671 patients with an uninformative BRCA1/2 result had already completed expanded testing. Most, 74 of 102 (73%), had been rereferred to medical genetics during a clinical visit related to cancer care. Those who had already completed additional testing were more likely to have a personal history of cancer (92% vs. 79%, p = 0.002) and live locally (p = 0.032). Invitation to complete updated testing through this study was sent to 372 people, and 116 (31%) consented to participate. For 142 of the 256 who did not proceed with testing through the study, proof of receipt of research information was available. In total, 22 pathogenic variants were reported in 21 of the 226 patients with updated testing from before and including our study: ATM (4), CHEK2 (4), LZTR1 (1), MUTYH (3), NBN (1), NF1 (1), NTHL1 (1), PALB2 (4), PMS2 (1), RAD50 (1), and SPINK1 (1). Many potential barriers of retesting were eliminated by removing personal costs or travel requirements. Still, only about 30% of patients agreed to participate, and a significant portion elected not to proceed. Future research could focus on the discovery of other factors that dissuade patients and what measures may better inform them on potential benefits.
Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III Nation
Litzow, Mark R. , Sun, Zhuoxin , Paietta, Elisabeth , Mattison, Ryan J. , Rowe, Jacob M. , Zhang, Yanming , Wieduwilt, Matthew J. , Liedtke, Michaela , Bergeron, Julie , Pratz, Keith W. , Dinner, Shira, Gore, Steven D. , Bhatnagar, Bhavana , Jeyakumar, Deepa , Little, Richard F. , Luger, Selina M. , Tallman, Martin S. , Lazarus, Hillard M. , Arber, Daniel A. , Mullighan, Charles G. , Willman, Cheryl L. , Frey, Noelle V. , Atallah, Ehab , Uy, Geoffrey L. , Lin, Tara L.

Mayo Clinic

Blood | December 7, 2022 | Volume: 140 | Issue: Supplement 2 | Pages: LBA-1-LBA-1

10.1182/blood-2022-171751 Get It

Characteristics of ulcerated and non‐ulcerated necrobiosis lipoidica
Hines, Alexander , Butterfield, Richard , Boudreaux, Blake , Bhullar, Puneet , Severson, Kevin J. , Davis, Mark D.P. , Pittelkow, Mark R. , Mangold, Aaron R. , McBane, Robert D. , Mangold, A R , Hines, Alexander S , Severson, Kevin J , Boudreaux, Blake W , Alavi, Afsáneh

Mayo Clinic

International Journal of Dermatology | December 7, 2022 | Volume: 62 | Issue: 6 | Pages: 790-796

10.1111/ijd.16529 | PMID 36479693 Get It

AbstractBackgroundNecrobiosis lipoidica (NL) is complicated by ulceration in up to 35% of cases.MethodsRetrospective study of patients with NL seen at our institution between January 1, 1992, and May 25, 2021, was conducted. Ulcerated NL (UNL, n = 83) and non‐ulcerated NL (NUNL, n = 233) groups were compared.ResultsTwenty‐six percent (83/316) of patients with NL experienced ulceration. UNL was significantly more likely to be painful (52% vs. 36%, P = 0.01), was more likely to have a lesion‐associated cutaneous malignancy (7% vs. 0%, P < 0.001), and had a larger median size (7 vs. 5 cm, P = 0.004) compared to NUNL. Vascular studies were performed on a subset of patients and revealed transcutaneous oxygen pressure (TcPO2) < 40 mm Hg in 53% and venous insufficiency in 62% with no significant differences between UNL and NUNL groups. In patients with unilateral ulceration, mean TcPO2 values (39.7 vs. 46.6 mm Hg), regional perfusion index <0.6 (29% vs. 14%), and TcPO2 < 40 mm Hg (43% vs. 14%) were worse in the ulcerated leg compared to the non‐ulcerated leg, but these differences were not statistically significant.ConclusionsUNL was more likely to be painful, develop lesion‐associated malignancy, and be larger in size compared to NUNL. There were no statistically significant differences in venous insufficiency, arterial Doppler/ankle brachial index, or TcPO2 values between UNL and NUNL patients, however, a significant portion of the cohort demonstrated abnormal vascular studies, particularly on TcPO2 and venous insufficiency testing.